Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This month the MRC Weatherall Institute of Molecular Medicine (WIMM) hosted the annual Regional Breast Cancer Academic Day, an event that brings together breast cancer teams from across the Thames Valley region. This year’s symposium involved the participation of over 70 attendees, including nurses, clinical trial managers, researchers and doctors.

In addition to the usual mix of internal and external speakers, this year's event was also an opportunity to highlight the contributions of Professor Adrian Harris, one of the organisers of the event. Professor Harris founded the Oxfordshire Breast Clinic in 1989. The event marked his official retirement from the clinic and from the National Health Service. Professor Harris will continue to lead a research group in the Department of Oncology.

The Harris group works on tumour angiogenesis and the role of Notch signalling, and hypoxia biology and its regulation. The ultimate aim of the research programme is to develop ways to improve the treatment of breast cancer and other tumour types, by blocking the blood supply to tumours. Professor Harris' group is one of the several research teams from the Department of Oncology within the WIMM, whose research focuses on cancer research. The Regional Breast Cancer Academic Day was sponsored by Eisai, Pierre Fabre, Novartis, Pfizer and Synthon.

Similar stories

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

OUH agrees long COVID research collaboration with Polarean

The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.